Iovance Biotherapeutics has increased its full-year 2026 total revenue guidance, citing strong U.S. demand for its cancer therapies, Amtagvi® (lifileucel) and Proleukin. The updated forecast represents a $55 million, or approximately 15%, increase at the midpoint compared to the prior range.
Key Details
- New Guidance: The company now expects full-year 2026 revenue to be between $410 million and $420 million.
- Previous Guidance: This is an increase from the prior range of $350 million to $370 million.
- Driver: The raised outlook is driven by sustained, strong patient demand and a manufacturing schedule that provides high visibility into third and fourth-quarter revenues.